PATENT CLAIM ANALYSIS

Application Number: 16032743
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2019-01
Patent Classification: ["514", "210210"]

Abstract:
This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.

Claim (Index 79):
The method of  claim 78 , wherein the cancer is selected from hepatocellular cancer, bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, prostate cancer, esophageal cancer, gall bladder cancer, pancreatic cancer, thyroid cancer, skin cancer, leukemia, multiple myeloma, chronic lymphocytic lymphoma, adult T cell leukemia, B-cell lymphoma, acute myelogenous leukemia, Hodgkin's or non-Hodgkin's lymphoma, Waldenstrom's Macroglubulinemia, hairy cell lymphoma, Burkett's lymphoma, glioblastoma, melanoma, and rhabdosarcoma.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 95.0
- Lexical Diversity: 1.13793
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15247499', '15971017', '15234690', '15624850', '15151259']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8086151942253424
- 35 USC 102 Novelty (BERT): 0.6337142990791876
- Combined Prediction Score: 0.791125104710727
- Mean Citation Score: 507.6831120000001
- Max Citation Score: 627.3497
- Similarity Product: 523.9720120027183

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test